CALR and thrombocytosis disease: Although the oncogenic mechanism of the mutant CALR is not fully elucidated, it has been hypothesized that the mutations enhance the binding capacity of CALR to TPOR, whose hyperactivation leads to enhanced megakaryocyte proliferation and thrombocytosis [15,16].